We recently described oncogenic and anti-apoptotic C-RAF germline mutations in patients with therapy-related acute myeloid leukemia (t-AML). Activation of the RAF effector ERK was restricted to transformed cells, suggesting the requirement for cooperating events in leukemogenesis. Western blot analysis of blast cells from patients with C-RAF germline mutations revealed loss of the tumor and metastasis suppressor RAF kinase inhibitor protein (RKIP). Immunohistochemistry of the patients' primary tumors revealed normal RKIP expression levels, indicating that the loss of RKIP is a somatic, t-AMLspecific event. In focus formation assays, the oncogenic potential of human mutant C-RAF was strongly influenced by expression levels of RKIP. Although the number of colonies formed by C-RAF S427G was significantly increased by RKIP silencing, the opposite was observed after RKIP overexpression. These results show that the loss of RKIP is a functional somatic event in carriers of C-RAF germline mutations, which contributes to the development of t-AML.
Introduction
Therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) are fatal long-term consequences of cytotoxic therapies for primary malignant and non-malignant diseases. 1 Both t-MDS/t-AML develop in a small but significant proportion of patients who have received chemotherapy and/or radiation, and it is increasingly recognized that these disorders arise on the basis of genetic susceptibility. 2, 3 Somatic mutations in genes of the RAS-RAF-MEK-ERK signal transduction cascade are present in many human neoplasms, including t-MDS/t-AML, and are thought to play a pivotal role in their pathogenesis. 4, 5 We recently described two germline mutations of the C-RAF proto-oncogene in patients with t-AML. 6 These substitutions showed oncogenic and anti-apoptotic properties in vitro and may have predisposed their carriers to this disorder. In tumors of patients with C-RAF germline mutations, ERK phosphorylationFas an indicator of RAF activationFwas restricted to transformed cells and absent in the normal surrounding tissue. This strongly argues for the requirement of additional alterations to fully unmask the oncogenic and/or anti-apoptotic potential of mutant C-RAF. In this study, we tested for a possible involvement of the RAF kinase inhibitor protein (RKIP), which has been identified as a negative regulator of RAF signaling. 7 
Materials and methods

Patients and samples
Clinical and genetic characteristics of the patients analyzed are presented in Table 1 . Samples were obtained and processed as described earlier. 6 The study was approved by the Institutional Review Board of the Medical University of Graz, Austria.
Western blot analysis and immunohistochemistry
Western blot was performed as reported earlier 6 Immunohistochemistry of paraffin-embedded primary tumor specimens was performed as described earlier using the above-mentioned RKIP antibody. 6 Methylation-specific PCR Approximately 1 mg of DNA was subjected to bisulfite modification using the CpGenome DNA modification Kit (Chemicon, Temecula, CA, USA) according to the manufacturer's instructions. CpGenome Universal Methylated DNA (Chemicon) was included in all experiments as a positive control. Methylationspecific PCR was performed as described by Al-Mulla et al. . For improved visualization of PCR products, fluorescent dyes were attached to the forward primers; NED for the methylated and FAM for the unmethylated primer. PCR products were subjected to fragment analysis on an A310 automated capillary sequencer using GeneScan analysis software (Applied Biosystems, Foster City, CA, USA).
DNA copy number-specific real-time PCR and sequence analysis
Assessment of DNA copy number was carried out as reported earlier.
6,9 RKIP (12q24.23) was set as a target gene with c-ABL (9q34.1) and FVIIIC (Xq28) as control genes. For sequence analysis, RKIP exons 1-4 were amplified from genomic DNA using the following primer pairs:
. PCR, gel electrophoresis and sequence analysis were carried out as reported. 6 Cell culture and functional assays Soft agar assays were performed as described 6 with the following modifications: NIH 3T3 cells were transfected with 200 ng pcDNA3 C-RAF S427G or vector DNA and 600 ng pcDNA3 FLAG-hRKIP (a gift from Walter Kolch) or vector DNA as a control, using Lipofectamine 2000 (Invitrogen, Paisley, UK). NIH 3T3 pBABE and NIH 3T3 RAF S427G cells were transfected with 500 nM RKIP or control siRNA using Lipofectamine 2000. Fortyeight hours after the transfection, 10 5 cells were seeded in soft agar. After 14 days of incubation, single cells and colonies within 3 areas per well were counted under the light microscope, and the fraction of cells growing out into colonies was calculated. The effect of modulating RKIP expression levels on the phosphorylation status of MEK-ERK and IKK, a surrogate marker for NF-k-B activation, 10 was assessed in NIH 3T3 cells constitutively expressing C-RAF S427G after the transfection of pcDNA3-FLAG-RKIP, or after the use of siRNA directed against endogenous RKIP (ON-TARGETplus SMARTpool L-049754-01-0010, Dharmacon Inc., Lafayette, CO, USA). Antibodies used for subsequent western blot analyses were anti-pERK, anti-ERK1/2, anti-IKK1/2 (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-pIKK1/2 (Cell Signaling Technology), anti-FLAG (Sigma-Aldrich) and anti-GAPDH (Ambion, Austin, TX, USA).
Apoptosis assays
As described earlier, NIH 3T3 cells stably expressing C-RAF S427G or the empty control vector were transfected with pcDNA3-FLAG-RKIP or siRNA targeting endogenous RKIP. 6 Forty-eight hours after the transfection, cells were treated for 24 h with 1 mM staurosporine, apoptosis was subsequently analyzed by flow cytometry after annexin V-propidium iodide staining. In addition, NIH 3T3 C-RAF S427G cells stably expressing pcDNA3-FLAG-RKIP or vector control were treated for 24 h with 1 mM staurosporine and analyzed in the similar manner.
Results and Discussion
To identify alterations enhancing the oncogenic and/or antiapoptotic properties of C-RAF germline mutations, we initially screened proteins and/or signaling pathways interacting with the MAPK (mitogen-activated protein kinase) pathway. Western blot analysis revealed the loss of RKIP in leukemic blast cells of both patients with C-RAF germline mutations, but not in any of the five t-AML control specimens (Figure 1 ). Other modulators, such as RAS and FLT3 6 or the PI3-Akt pathway, were found to be unaffected (data not shown). Thereafter, we performed immunohistochemistry of the patients' primary tumors and four colon carcinoma control specimens. Normal RKIP expression levels were observed in both patients' primary malignancies, indicating that the loss of RKIP in leukemic cells is a somatic event (Figure 2 ). Although we were unable to measure RKIP mRNA expression levels owing to the shortage of leukemic samples, a concomitant decrease in both RKIP protein and mRNA expression has been shown in various solid tumors. 11, 12 We then searched for mechanisms underlying decreased RKIP expression in t-AML. The coding region of RKIP was sequenced for inactivating mutations and the DNA copy number assessed to screen for gene deletions. No abnormalities could be detected in any sample (data not shown). Methylation of the RKIP promoter was investigated using methylation-specific PCR of a CpG-rich cluster as described earlier. 8 From both patients, leukemic DNA as well as constitutional DNA extracted from normal tissues were analyzed. DNA obtained from the five t-AML control samples was also included in this analysis. Methylation of the RKIP promoter was observed in both leukemic and leukemia-unaffected material of the patient with C-RAF S427G but not in any other samples (data not shown). Abbreviation: t-AML, therapy-related acute myeloid leukemia.
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Therefore, these data exclude RKIP promoter methylation as a cause for RKIP silencing.
The level of RKIP expression plays a crucial role in cellular transformation, cancer cell invasion and drug-induced apoptosis.
13,14 RKIP in particular has been shown to inhibit the oncogenic capacity of C-RAF. 7 To test whether this also holds true for mutated C-RAF, we performed NIH 3T3 colony formation assay after the co-transfection of C-RAF S427G with RKIP and empty vector. Transfection of RKIP significantly decreased the number of colonies in soft agar (P ¼ 0.00028) (Figures 3a and c) , indicating an inhibitory effect of RKIP on the oncogenic potential of mutant C-RAF. Parental NIH 3T3 cells transfected only with empty vector or RKIP were included as controls; both failed to form colonies in three independent experiments (data not shown). To corroborate these data, we performed NIH 3T3 focus formation assays with C-RAF S427G and a concomitant RKIP knockdown. As compared with control siRNA, siRNA targeting RKIP significantly increased the number of colonies formed by C-RAF S427G (P ¼ 0.00137), which further proved the pivotal role of RKIP in suppressing the oncogenic properties of human mutant C-RAF (Figures 3b and d) . Again, parental NIH 3T3 cells that were treated with RKIP or control Loss of RKIP in t-AML A Zebisch et al siRNA failed to form colonies in three independent experiments (data not shown).
We next tested the effects of RKIP on the anti-apoptotic properties of mutant C-RAF. As shown before, NIH 3T3 cells expressing C-RAF S427G showed a significant reduction in apoptosis after treatment with staurosporine. 6 However, RKIP overexpression and RKIP siRNA knockdown did not have any further effect on the anti-apoptotic effects of C-RAF S427G (data not shown). These results indicate that RKIP selectively inhibits the transforming potential of mutant C-RAF by its ability to sustain growth in soft agar. The anti-apoptotic properties of mutant C-RAF, which may be important for tumor growth in vivo, are unaffected by RKIP expression levels.
RKIP has been shown to be a negative regulator of RAF and NF-k-B signaling. 7, 10 Although the ERK pathway was activated in leukemic blast cells of both patients, 6 activation of NF-k-B in the patient with C-RAF I448VFas assessed by IKK phosphorylationFwas not significantly increased as compared with the five t-AML control samples (data not shown). Limited sample quality and quantity excluded analysis of leukemic material of the patient with C-RAF S427G. In addition, overexpression and siRNA knockdown experiments of RKIP in NIH 3T3 cells transfected with C-RAF S427G were performed, and the phosphorylation status of MEK-ERK and IKK was assessed. However, activation of both pathways did not change significantly under these conditions (data not shown), suggesting other, yet unidentified effector pathways that contribute to the oncogenic properties of mutant C-RAF.
There is increasing evidence that genetic predisposition plays an essential role in the development of t-MDS/t-AML. A number of polymorphisms in genes encoding drug-metabolizing enzymes, or of major DNA damage response and repair pathways have been associated with altered risk of t-MDS/ t-AML. 2, 15 Of particular interest are mutations in genes leading to constitutive activation of the RAF-MEK-ERK signaling cascade. Children with neurofibromatosis type 1 are at increased risk of developing both primary and treatment-related malignancies, including t-MDS/t-AML. 16, 17 Indeed, treatment of Nf1 knockout mice with radiotherapy and alkylating agents lead to a significant increase in myeloid neoplasms. 18, 19 We recently described germline mutations in the C-RAF proto-oncogene that might predispose their carriers to the primary tumor, as well as to t-AML. 6 Meanwhile, C-RAF germline mutations have also been detected in a substantial proportion of patients with Noonan and LEOPARD syndrome. 20, 21 Not unexpectedly, both syndromes are associated with de novo and therapy-related leukemias. [22] [23] [24] [25] Silencing of the tumor and metastasis suppressor RKIP occurs in several solid neoplasms, but has not yet been described in hematologic malignancies. 26, 27 In this study, we were able to identify the loss of RKIP expression in leukemic cells of two patients with C-RAF germline mutations and t-AML. We could show that cellular transformation by C-RAF is significantly inhibited by RKIP, indicating that the loss of RKIP most likely contributed to the development of t-AML in these patients. In a model of therapy-related leukemogenesis, it seems plausible that the loss of RKIPFand further genetic events as indicated by abnormal karyotypesFis a consequence of genotoxic therapies. However, it might also be the result of increased genetic instability caused by the C-RAF germline mutation itself. Indeed, the induction of genetic instability by oncogenic mutations was recently shown for B-RAF. 28 These findings propose a model of therapy-related leukemogenesis as an interplay between a predisposing oncogenic mutation and somatic, leukemia-specific events.
